Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

The ClariVein device using liquid Polidocanol and foam for the treatment of great saphenous vein incompetence : A dose finding study.

- candidate number10206
- NTR NumberNTR3009
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR29-jul-2011
- Secondary IDs37669 ABR
- Public TitleThe ClariVein device using liquid Polidocanol and foam for the treatment of great saphenous vein incompetence : A dose finding study.
- Scientific TitleThe ClariVein device using liquid Polidocanol and foam for the treatment of great saphenous vein incompetence : A dose finding study.
- ACRONYMClariVein dose-finding study.
- hypothesisOur hypothesis is that there is no difference in outcome between patients having their incompetent GSV treated with ClariVein therapy using Polidocanol 2%, 3% liquid or 1% foam.
- Healt Condition(s) or Problem(s) studiedVaricosis, Incompetence of the great saphenous vein, Minimally invasive, ClariVein
- Inclusion criteria1. Patients who are first time treated for incompetence of the VSM, proven with duplex ultrasound examination;
2. CEAP classification C2-C4;
3. All patients with informed consent.
- Exclusion criteria1. Age < 18 years and or incompetent;
2. Life expectancy of less than 6 months;
3. Previous surgery for GSV incompetence;
4. Occlusion of deep venous system;
5. Pregnancy;
6. No informed consent;
7. Extreme obesity: BMI> 40;
8. Very tortuous pace of GSV which bends at an angle of >90 º or more twists follow each other;
9. Allergy or contraindication to Polidocanol;
10. GSV bigger than 12mm.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingSingle
- controlNot applicable
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-sep-2011
- planned closingdate1-sep-2012
- Target number of participants600
- InterventionsThe procedure will be identical for every patient, except for the dosage and form of the chemical component. The patient will be examined by ultrasound to identify the GSV at the knee level. This will be done while the patient is standing. After the GSV is identified the patient will take place on the operating table and a Venflon needle will be inserted at knee level and a sheath will be introduced to ensure access for the ClariVein® system. The ball tip of ClariVein® system is placed 2cm distal to the saphenofemoral junction, measured from the hard shoulder of the saphenofemoral junction. The wire will be activated at the setting of 3500 rpm and after 3 seconds it will be moved distally at a steady pace of 1.0 – 2.0mm / second, 6 seconds per centimeter. With the rotating wire applying mechanical damage to the veinwall 5 mL Polidocanol is injected into the GSV. After 30 cm of the GSV is treated the system is removed from the vein. Duplex ultrasonography will be performed after the procedure to visualize and quantify the spasm of the obliterated GSV segment and confirm patency of the deep venous system. Directly after the procedure a class 2 thigh stocking is applied to the leg for 48 hours and 2 weeks during daytime. There is no need for any form of anesthesia or analgesia during the procedure. Patients can resume their daily activities immediately. Because of the learning curve the physician operating the device has to acknowledge the performance of at least 10 procedures with ClariVein®, before treating patients in the study group. Training will be provided by Vascular Insights who will assist and train the physician for the first 10 ClariVein® treatments. Foam preparation:Foam will be made by the physician with 1 mL of 1% Polidocanol and 4 mL of room air in a 5mL Luerlock syringe that will be connected by a 3-way stop-cock with another 5mL Luerlock syringe according to the Tessari method (Figure 1). Through rapid alternating movements foam will be created before the wire is activated and pullback is started as the foam consistency.
- Primary outcomeOur primary endpoint is the anatomical success rate of the treated GSV after 6 months, defined as occlusion confirmed by ultrasound of at least 85% which correlates to 24,5cm of the treated 30cm.
- Secondary outcome1. Mean VCSS change (evaluated at mentioned time points);
2. Pain score during procedure (VAS);
3. Two weeks post-preocedure pain score (VAS);
4. Health status (using the SF36 the general health status will be evaluated at mentioned time points);
5. Disease related quality of life (using the AVVQ, the quality of life related to the disease will be evaluated at mentioned time points);
6. Adverse events;
7. Patient satisfaction measured in separate scores.
- TimepointsFollow-up will take place after 6 weeks and 6 months while history and quality of life questionnaires are conducted, physical examination and duplex scan are also performed.
- Trial web siteN/A
- statusplanned
- Sponsor/Initiator Academic Hospital Maastricht (AZM)
- Funding
(Source(s) of Monetary or Material Support)
Vascular Insights
- PublicationsN/A
- Brief summaryVaricose veins due to incompetence of the Greater Saphenous Vein (GSV) are very common and are cause of many complaints. Treatment for an incompetent GSV is very common in the Netherlands in order to treat complaints and to prevent complications such as dermatoliposclerosis and ulcer formation. In the last years there are numerous new minimal invasive methods for closure of the GSV. Although Stripping is still considered the gold standard, the new minimal invasive methods are more commonly used. A new product has been introduced: The ClariVein® system. This minimal invasive procedure has the advantage over the other minimal invasive methods, that is does not require any form of tumescent anesthesia. The ClariVein® system makes use of a chemical and a mechanical component to occlude the GSV. The mechanical component damages the endothelium of the vein via a rotating wire. Yet, there is a choice of different sclerosant applications in order to achieve maximal endothelium damage. Our study tries to identify the best sclerosant dosage and form for the ClariVein® system in order to occlude the GSV permanently.

Only The Netherlands will be recruited.
- Main changes (audit trail)
- RECORD29-jul-2011 - 25-feb-2012

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar